Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860871 | 0.91 | KMT2A (0.48) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5861027 | 0.89 | KMT2A (0.47) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5862666 | 0.89 | KMT2A (0.49) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5862652 | 0.88 | KMT2A (0.44) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5859782 | 0.88 | KMT2A (0.47) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5859898 | 0.88 | KMT2A (0.47) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5860995 | 0.88 | KMT2A (0.48) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5861059 | 0.87 | KMT2A (0.46) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5862642 | 0.86 | KMT2A (0.57) | KMT2ANPSR1ITGB1ITGA4CYP2D6 | |
| SCHEMBL5860038 | 0.84 | KMT2A (0.45) | KMT2ANPSR1ITGB1ITGA4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-6465513-B1 | SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | claimed |
| US-7115768-B2 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | GRANT FRANCINE S (US) | 2003-07-17 | — | — | US | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KMT2A 1620/4885NPSR1 1381/4885ITGB1 53/4885 |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KMT2A 1620/4885NPSR1 1381/4885ITGB1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.